Kraiem ended up at the Sylvester Comprehensive Cancer Center in 2022. He has a rare and aggressive form of soft tissue sarcoma. Three years of chemo, radiation and surgeries later, he still has tumors ...

A next-generation "armored" CAR T cell therapy showed promising results in a small study of patients whose B-cell lymphomas continued to resist multiple rounds of other cancer treatments ...

Despite these advancements, more than 50% of patients with lymphoma do not have long-term remission with anti-CD19 CAR T-cell therapy. These patients have limited treatment options and poor prognoses.

What if the key to reducing your chronic pain was not in tackling the symptoms, but in regulating your emotions? A recent ...

Cancer patients from countries in Gulf, Europe and Africa are making beeline to seek advanced CAR-T cell therapy in India, as most of these countries doesn't still have access to the treatment ...

NecstGen will use Astraveus’ Lakhesys product at its facility in Leiden to determine its potential to reduce costs and increase efficiency in CAR-T manufacturing compared to current industry ...

Kraiem is just happy to be proof of it. “If it wasn’t for the music therapy and the other services that I receive at Sylvester and my family, I wouldn’t have made it through this thing ...

Genocury Biotech, a clinical-stage biotechnology pioneer redefining in vivo cell engineering through its proprietary Vivoexpress platform, announced groundbreaking clinical data from its noval in vivo ...

A study from the American Journal of Psychiatry suggests that psychotherapy is becoming more accessible to people. The study ...